The Effect of Transcranial Direct Current Stimulation (tDCS) on Motor and Cognitive Functions in Idiopathic Fallers
The concurrent performance of two tasks, i.e., dual tasking (DT), is a common and ubiquitous every day phenomena. For example, people frequently walk while talking on a cellphone or drive while talking to a passenger. Often, the performance of one or more of these simultaneously performed tasks may deteriorate when another task is carried out at the same time, even in healthy young adults. This reduction in performance is referred to as the DT deficit or DT cost and is typically much higher in Idiopathic Fallers (IF) than in age-matched controls. In this population the DT cost impairs the gait pattern, as manifested, for example, in increased gait variability, exacerbating instability and fall risk.
In the proposed study, would be evaluated the effects of tDCS on dual tasking performance following tDCS.
The researchers expect that stimulation of the Pre Frontal Cortex (PFC) (using tDCS) will increase DT performance and prefrontal activation.
Studieoversikt
Detaljert beskrivelse
tDCS intervention: Noninvasive tDCS will be delivered by study personnel uninvolved with any other study procedures. In the study will be used a battery-driven electrical stimulator. Stimulation and sham condition will be performed based on previous studies. Briefly, the anode will be placed over the PFC and the cathode over the right supraorbital region. The real tDCS condition will consist of 20 min of continuous stimulation at target intensity of 1.5 mA. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions. For the sham condition, an inactive stimulation protocol would be followed, as compared with an 'off-target' active protocol, in order to minimize participant risk.
Pre- and post-tDCS assessments will include:
Gait assessment: Gait parameters will include both spatial and temporal parameters obtained using body fixed wearable sensors (accelerometers and gyroscopes) [Weiss et al. 2015; Ben et al. 2015]. Parameters will include (but are not limited to) gait speed, stride length and stride time as well as rhythmicity measures such as stride to stride variability and gait regularity.
Fall history and fear of falling will also be assessed (e.g., Falls Efficacy Scale International, FES-I) to further characterize the cohort and explore possible confounds.
Cognitive assessment: A detailed computerized cognitive battery that has been used extensively at TASMC in different cohorts [Dwolatzky et al. 2003;Hausdorff et al. 2006;Springer et al. 2006;Yogev et al. 2005;Aarsland et al. 2003] will quantify several cognitive domains including working memory, executive function, verbal function, problem solving, a global cognitive score, and attention.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Massachusetts
-
Roslindale, Massachusetts, Forente stater, 02121
- Rekruttering
- Hebrew Rehabilitation Center / Harvard Medical School
-
Underetterforsker:
- Lewis Lipsitz, MD
-
Hovedetterforsker:
- Brad Manor, PhD
-
Ta kontakt med:
- Brad Manor, PhD
- Telefonnummer: 617-632-8884
- E-post: BradManor@hsl.harvard.edu
-
Ta kontakt med:
- Lewis Lipsitz, MD
-
-
-
-
-
Tel Aviv, Israel, 64239
- Rekruttering
- Laboratory for Gait and Neurodynamics, Tel Aviv Sourasky Medical Center
-
Ta kontakt med:
- Jeffrey Hausdorff, PhD
- E-post: jhausdor@tasmc.health.gov.il
-
Ta kontakt med:
- Talia Herman, MScPT
- E-post: talit@tasmc.health.gov.il
-
Underetterforsker:
- Talia Herman, MSc
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- age 65-85 years,
- ability to walk for 6 minutes unassisted,
- adequate vision capabilities, and
- stable medications for the past month.
Exclusion Criteria:
- diagnosis of stroke, Parkinson's disease, peripheral neuropathy or other neurologic disorder,
- lower-extremity deformity, joint replacement, severe arthritis or other diagnosed musculoskeletal disorder that may influence gait,
- orthostatic hypotension, recent history of syncope or vertigo,
- myocardial infarction or surgery within the past 6 months,
- any unstable medical condition,
- psychiatric co-morbidity (e.g., major depressive disorder as determined by DSM V criteria),
- likely dementia (i.e., Mini Mental State Exam score < 24 or based on DSM V),
- sedating medications (sedatives, anti-psychotics, hypnotics, anti-depressants,
- colorblindness (confounder for cognitive assessment), or
- contraindications to tDCS
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: tDCS
The active tDCS condition will consist of 4 visit: During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets:
The tDCS condition will be randomized and double blinded |
The active tDCS condition will consist of 20 min of continuous stimulation.
This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Immediate change in gait speed
Tidsramme: 1st measure will be taken at baseline ans 2nd immediate post intervention
|
Gait speed will be assessed under usual and dual task conditions and while negotiating physical obstacles, using a sensorized 7 meter carpet (PKMAS) and wearable body fixed sensors.
These measures will be compared to baseline performance.
|
1st measure will be taken at baseline ans 2nd immediate post intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
fNIRS related frontal lobe activation - changes in tissue oxygenation
Tidsramme: 1st measure will be taken at baseline ans 2nd immediate post intervention
|
fNIRS will be used to investigate the role of the frontal lobe in DT walking and how it is affected by tDCS.The fNIR system provides with real-time monitoring of tissue oxygenation in the brain as subjects take different tests.
|
1st measure will be taken at baseline ans 2nd immediate post intervention
|
|
Changes in cognitive performance - Executive Function composite score
Tidsramme: 1st measure will be taken at baseline ans 2nd immediate post intervention
|
The NeuroTrax software uses tests of cognitive performance that measure similar cognitive functions to traditional paper-based tests.
|
1st measure will be taken at baseline ans 2nd immediate post intervention
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Nir Giladi, Prof., Tel Aviv Sourasky medical Center, Tel Aviv, Israel
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Zhou J, Hao Y, Wang Y, Jor'dan A, Pascual-Leone A, Zhang J, Fang J, Manor B. Transcranial direct current stimulation reduces the cost of performing a cognitive task on gait and postural control. Eur J Neurosci. 2014 Apr;39(8):1343-8. doi: 10.1111/ejn.12492. Epub 2014 Jan 20.
- Schneider N, Dagan M, Katz R, Thumm PC, Brozgol M, Giladi N, Manor B, Mirelman A, Hausdorff JM. Combining transcranial direct current stimulation with a motor-cognitive task: the impact on dual-task walking costs in older adults. J Neuroeng Rehabil. 2021 Feb 1;18(1):23. doi: 10.1186/s12984-021-00826-2.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- TASMC-16-NG-0699-CTIL
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .